GLP-1 medications and heart failure: 22,000-patient systematic review finds clear benefit in HFpEF

TL;DR

A 2025 systematic review and meta-analysis published in Cardiovascular Endocrinology and Metabolism (PMC12445413) synthesised 16 randomised controlled trials involving 22,000 patients and found that GLP-1 receptor agonists significantly reduced heart failure hospitalisations, cardiovascular death, and all-cause mortality in patients with heart failure - particularly heart failure with preserved ejection fraction (HFpEF). Semaglutide showed the strongest signal. GLP-1 medications also improved functional capacity (six-minute walk test) and quality of life compared to placebo.

Heart failure with preserved ejection fraction (HFpEF) - the form where the heart pumps normally but is too stiff to fill adequately - affects an estimated 3.4 million people in the US and has long been among cardiology's most frustrating conditions to treat. Unlike heart failure with reduced ejection fraction (HFrEF), where multiple drug classes have proven mortality benefits, HFpEF has resisted pharmacotherapy for decades. The GLP-1 class has emerged as the most exciting new therapeutic option in this space.

Understanding HFpEF: the heart failure where the pump isn't broken

In standard heart failure (HFrEF), the left ventricle weakens and cannot pump enough blood with each beat - ejection fraction (the percentage of blood pumped out with each heartbeat) falls below 40%. In HFpEF, the ejection fraction is preserved at 50% or above, but the heart muscle is abnormally stiff and cannot relax properly between beats. This means the heart cannot fill with enough blood to then pump out, despite each pump action being mechanically intact.

HFpEF is strongly associated with obesity, hypertension, diabetes, and metabolic syndrome. Adipose tissue - particularly the fat that accumulates around the heart (epicardial fat) - promotes inflammation and fibrosis of the cardiac muscle, driving the stiffness. This metabolic-cardiac link is why GLP-1 medications, which address obesity, insulin resistance, and inflammation simultaneously, are particularly well-positioned to help in HFpEF where metabolic drivers predominate.

The 22,000-patient systematic review: key findings

The review analysed 16 randomised controlled trials across the GLP-1 drug class (semaglutide, liraglutide, dulaglutide, exenatide, albiglutide) and found:

• Cardiovascular death and hospitalisation for heart failure (composite endpoint): significant reduction in GLP-1 vs placebo arms (hazard ratio approximately 0.87-0.91, p less than 0.01)
• All-cause mortality: significant reduction (HR approximately 0.88, p less than 0.05)
• Hospitalisation for heart failure specifically: significant reduction (HR approximately 0.82-0.86)
• Six-minute walk test distance (functional capacity): significant improvement - GLP-1 users walked further than placebo in standardised assessments
• Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life score: significant improvement, reflecting reduced symptoms and better daily function
• Body weight: significant reduction, contributing to cardiac unloading and reduced epicardial fat

Across the pooled analysis, semaglutide showed the strongest individual signal - consistent with the STEP-HFpEF and STEP-HFpEF DM trial results that formed a large part of the evidence base.

STEP-HFpEF: the definitive trial in detail

The STEP-HFpEF trial (semaglutide 2.4 mg weekly, n=529, 52 weeks) and STEP-HFpEF DM (patients with type 2 diabetes, n=616, 52 weeks) provided the most definitive HFpEF evidence to date. Pooled results from these two trials showed:

• KCCQ clinical summary score improvement: +7.8 points vs +4.3 for placebo (treatment difference +3.5 points, p less than 0.001)
• Six-minute walk distance improvement: +17.3 m vs +2.8 m for placebo (treatment difference +14.5 m, p less than 0.001)
• Body weight reduction: -13.3% semaglutide vs -2.6% placebo
• CRP (inflammatory marker) reduction: -43.5% vs -7.3% - a very large anti-inflammatory effect
• Composite of cardiovascular death or worsening heart failure: HR 0.77 (95% CI 0.60-0.98) - borderline significant reduction

The magnitude of functional improvement - 14.5 metres on the walk test and 3.5 points on the KCCQ - may seem modest in absolute terms, but in HFpEF research, where many trials have failed entirely to show any benefit, these are clinically meaningful differences.

Why HFpEF may be where GLP-1 medications shine most

The systematic review's analysis points to several reasons why HFpEF may be particularly responsive to GLP-1 therapy:

The obesity-inflammation-fibrosis loop

HFpEF pathophysiology is driven by adipose tissue inflammation. Epicardial fat (fat around the heart) and visceral fat produce pro-inflammatory cytokines that promote myocardial fibrosis - the stiffening that impairs filling. GLP-1 medications reduce both epicardial and visceral fat, reduce systemic inflammation (the CRP reductions in STEP-HFpEF were particularly striking), and may directly improve cardiac muscle relaxation through GLP-1 receptor activation in cardiomyocytes.

Blood pressure and preload reduction

Weight loss from GLP-1 therapy reduces blood pressure - both systolic and diastolic. In HFpEF, elevated blood pressure is both a cause and an aggravator of the condition. Lower blood pressure reduces the pressure the stiffened heart must overcome to fill properly. This is a straightforward mechanical benefit that contributes to symptom improvement independently of any direct cardiac effect.

The HFrEF paradox

Notably, the systematic review found a less consistent signal in heart failure with reduced ejection fraction (HFrEF). Some analyses have even raised concerns about GLP-1 medications in HFrEF - the LIVE trial found liraglutide increased adverse events in HFrEF patients. The review authors note this divergence: GLP-1 medications appear beneficial in HFpEF but should be used cautiously in HFrEF, where the metabolic drivers of disease are less dominant. This distinction has significant clinical implications for prescribing.

Nutritional considerations for heart failure patients on GLP-1 therapy

Heart failure patients on GLP-1 medications face specific nutritional challenges. Many heart failure patients are already at risk of malnutrition - "cardiac cachexia" (muscle wasting associated with advanced heart failure) is a recognised clinical syndrome. Adding GLP-1-driven appetite suppression to a patient with already-reduced food intake can accelerate muscle mass loss.

Key concerns for this population:

• Protein intake: minimum 1.2 g/kg/day is recommended for GLP-1 users generally; heart failure patients may need even more to prevent cardiac muscle loss
• Magnesium: critical for cardiac rhythm and muscle function, often low in heart failure patients and further reduced by GLP-1-associated dietary restriction
• Thiamine (vitamin B1): frequently deficient in heart failure patients, particularly those on diuretics, and essential for cardiac energy metabolism
• Coenzyme Q10: mitochondrial nutrient with particular relevance in cardiac muscle; GLP-1-driven dietary restriction may reduce CoQ10 intake

GLP-1 Shield addresses the documented nutrient gaps of GLP-1 medications - B12, vitamin D, magnesium, zinc, and iron - that are relevant across the patient population, including those with heart failure. Heart failure patients specifically should discuss their full nutritional supplementation plan with their cardiologist.

Frequently asked questions

What is HFpEF and why is it hard to treat?

HFpEF (heart failure with preserved ejection fraction) is a form of heart failure where the heart pumps normally but is too stiff to fill adequately. It is strongly linked to obesity, hypertension, and metabolic syndrome. Unlike heart failure where the pump is weakened (HFrEF), HFpEF does not respond to the same drug classes - diuretics help symptoms but few drugs have shown clear mortality or hospitalisation benefits. GLP-1 medications are the most promising new treatment approach in HFpEF.

Which GLP-1 medication is best for heart failure?

Semaglutide has the strongest evidence base for HFpEF specifically, based on the STEP-HFpEF and STEP-HFpEF DM trials. The 22,000-patient systematic review found semaglutide produced the most consistent benefits across functional capacity, quality of life, and hospitalisation endpoints. However, GLP-1 medications should not be started or stopped for cardiovascular indications without consultation with a cardiologist - particularly for HFrEF patients, where the evidence is less clear.

Can Ozempic help with heart failure?

Based on current evidence, semaglutide (the active ingredient in Ozempic and Wegovy) can improve symptoms, functional capacity, and quality of life in HFpEF patients who have obesity - and may reduce hospitalisations. The evidence is strongest from the STEP-HFpEF trials. For HFrEF (where the pump is weakened), the evidence is less consistent and there are some safety signals. Heart failure patients should discuss GLP-1 therapy specifically with their cardiologist.

Is weight loss from GLP-1 medications good or bad for heart failure?

In HFpEF with obesity, weight loss is beneficial: it reduces epicardial fat, lowers blood pressure, decreases cardiac workload, and reduces inflammation driving myocardial fibrosis. The STEP-HFpEF trials showed large weight losses (13.3%) alongside significant symptom improvements. In advanced HFrEF, weight loss can be harmful if it accelerates muscle wasting or reduces cardiac reserve. The type of heart failure matters significantly for this question.